Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) Mice

Journal of Pharmaceutical Sciences

Volumn 96, Issue 12, 2007, Pages 3478-3484

  Oswald, Stefan ^a   Koll, Christiane ^a   Siegmund, Werner ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Absorption; Disposition; Drug transport; Ezetimibe; mdr1; P glycoprotein

Indexed keywords

ANTILIPEMIC AGENT; EZETIMIBE; GLUCURONIDE; GLYCOPROTEIN P;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; URINARY EXCRETION;

EID: 35649019126     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20996     Document Type: Article

References (20)

1. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. 2004. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-1204.
2. Dujovne CA, Ettinger MP, Mcneer JF, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP. 2002. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, Ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90:1092-1097.
3. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. 2005. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467-494.
4. Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, von Bergmann K, Siegmund W. 2006. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 79:206-217.
5. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Maxwell SE, Kosoglou T, Murphy G, Gottesdiener K, Robson R, Paolini JF. 2006. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J Clin Pharmacol 46:328-336.
6. Kosoglou T, Statkevich P, Fruchart JC, Pember LJ, Reyderman L, Cutler DL, Guillaume M, Maxwell SE, Veltri EP. 2004. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 20:1197-1207.
7. Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T, Maxwell SE. 2004. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 42:512-518.
8. Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W, Siegmund W. 2006. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clin Pharmacol Ther 80:477-485.
9. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W. 2006. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharmacol Exp Ther 318:1293-1299.
10. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
11. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. 1997. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with P SC833. J Clin Invest 100:2430-2436.
12. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
13. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. 1997. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028-4033.
14. Oswald S, Scheuch E, Cascorbi I, Siegmund W. 2006. A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1 B1. J Chromatogr B Analyt Technol Biomed Life Sci 830:143-150.
15. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A. 1999. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J Pharm Sci 88:1281-1287.
16. Kivisto KT, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF. 2004. Characterisation of cerivastatin as a P-glycoprotein substrate: Studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn Schmiedebergs Arch Pharmacol 370:124-130.
17. Yamaguchi H, Yano I, Saito H, Inui K. 2002. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exp Ther 300:1063-1069.
18. Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, Schinkel AH. 2000. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol 57:188-197.
19. Lam P, Wang R, Ling V. 2005. Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice. Biochemistry 44:12598-12605.
20. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686.